NCT05515575 - A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 23, 2022

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions

Sarcoma,Soft TissueSarcoma Uterus

Interventions

DRUG

Niraparib

Each patient will receive niraparib daily in 21-day cycles until disease progression or unacceptable toxicity. Mandatory baseline tumor biopsies will occur during study screening, if feasible.

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11725

Memorial Sloan Kettering Cancer Center Suffolk- Commack (Limited Protocol Activities), Commack

07920

Memorial Sloan Kettering Cancer Center (Limited Protocol Activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale